{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:00:56Z","timestamp":1764169256275,"version":"3.46.0"},"reference-count":37,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"DOI":"10.31744\/einstein_journal\/2025ae1552","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:55:38Z","timestamp":1764168938000},"source":"Crossref","is-referenced-by-count":0,"title":["Implementation of positron emission tomography radiopharmaceuticals labeled with Gallium-68 in a hospital radiopharmacy: experience with more than 7,500 patients"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-7381","authenticated-orcid":false,"given":"Lilian Yuri Itaya","family":"Yamaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-6238","authenticated-orcid":false,"given":"Marycel Rosa Felisa Figols","family":"de Barboza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-5760","authenticated-orcid":false,"given":"Luciana","family":"Malavolta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-1324","authenticated-orcid":false,"given":"Leonardo Lima","family":"Fuscaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4668","authenticated-orcid":false,"given":"Jorge Mej\u00eda","family":"Cabeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7481-7142","authenticated-orcid":false,"given":"Solange Amorim","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1941-7899","authenticated-orcid":false,"given":"Gilberto","family":"Szarf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5416-5439","authenticated-orcid":false,"given":"Marcelo Livorsi","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-4103","authenticated-orcid":false,"given":"Taise","family":"Vitor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-3371","authenticated-orcid":false,"suffix":"Neto","given":"Guilherme de Carvalho","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6753-4697","authenticated-orcid":false,"given":"Jairo","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-3248","authenticated-orcid":false,"given":"Marcos Roberto Gomes","family":"de Queiroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"5","key":"key20251126145529_B1","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3390\/cancers12051312","article-title":"Insight into the development of PET radiopharmaceuticals for oncology","volume":"12","author":"Lau","year":"2020","unstructured":"1 Lau J, Rousseau E, Kwon D, Lin KS, B\u00e9nard F, Chen X. Insight into the development of PET radiopharmaceuticals for oncology. Cancers (Basel). 2020;12(5):1312.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"key20251126145529_B2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2967\/jnumed.107.047787","article-title":"Recommendations on the use of 18F-FDG PET in oncology","volume":"49","author":"Fletcher","year":"2008","unstructured":"2 Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508.","journal-title":"J Nucl Med"},{"issue":"6","key":"key20251126145529_B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.apradiso.2012.10.012","article-title":"Past, present and future of 68Ge\/68Ga generators","author":"Rosch","year":"2013","unstructured":"3 Rosch, F. Past, present and future of 68Ge\/68Ga generators. Appl Radiat Isot. 2013(6):24:30.","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"key20251126145529_B4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","article-title":"Good practices for 68Ga radiopharmaceutical production","volume":"7","author":"Nelson","year":"2022","unstructured":"4 Nelson BJ, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68Ga radiopharmaceutical production. EJNMMI Radiopharm Chem. 2022;7(1):27.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"key20251126145529_B5","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","article-title":"Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors","volume":"17","author":"Kwekkeboom","year":"2010","unstructured":"5 Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17(1):R53-73.","journal-title":"Endocr Relat Cancer"},{"issue":"10231","key":"key20251126145529_B6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","unstructured":"6 Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020 Apr 11;395(10231):1208-16.","journal-title":"Lancet"},{"issue":"7","key":"key20251126145529_B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.apradiso.2012.08.011","article-title":"A new automated NaCl based robust method for routine production of gallium-68 labeled peptides","volume":"76","author":"Schultz","year":"2013","unstructured":"7 Schultz MK, Mueller D, Baum RP, Leonard Watkins G, Breeman WA. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot. 2013;76(7):46-54.","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"key20251126145529_B8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.apradiso.2012.09.010","article-title":"Automation synthesis modules review","volume":"76","author":"Boschi","year":"2013","unstructured":"8 Boschi S, Lodi F, Malizia C, Cicoria G, Marengo M. Automation synthesis modules review. Appl Radiat Isot. 2013;76(6):38-45.","journal-title":"Appl Radiat Isot"},{"issue":"9","key":"key20251126145529_B9","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"68Ga-DOTATOC imaging of neuroe ndocrine tumors: a systematic review and metaanalysis","volume":"58","author":"Graham","year":"2017","unstructured":"9 Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC imaging of neuroe ndocrine tumors: a systematic review and metaanalysis. J Nucl Med. 2017;58(9):1452-8.","journal-title":"J Nucl Med"},{"issue":"1","key":"key20251126145529_B10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","unstructured":"10 Chang CA, Pattison DA, Tothill RW, Kong G, Akhurst TJ, Hicks RJ, et al. (68)Ga-DOTATATE and (18)F-FDG PET\/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16(1):22.","journal-title":"Cancer Imaging"},{"issue":"5","key":"key20251126145529_B11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00259-010-1720-x","article-title":"Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine","volume":"38","author":"Kroiss","year":"2011","unstructured":"11 Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38(5):865-73.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"key20251126145529_B12","first-page":"763","article-title":"Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas","volume":"46","author":"Henze","year":"2005","unstructured":"12 Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46(5):763-9.","journal-title":"J Nucl Med"},{"issue":"10","key":"key20251126145529_B13","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","article-title":"Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE","volume":"37","author":"Virgolini","year":"2010","unstructured":"13 Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004-10.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"key20251126145529_B14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2214\/AJR.18.19881","article-title":"Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET\/CT","volume":"211","author":"Sanli","year":"2018","unstructured":"14 Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJ, Kuyumcu S, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET\/CT. AJR Am J Roentgenol. 2018;211(2):267-77.","journal-title":"AJR Am J Roentgenol"},{"key":"key20251126145529_B15","first-page":"12","article-title":"Labeling of DOTATATE with 68Ga: preliminary studies at IPEN - CNEN\/SP","author":"Costa","year":"2009","unstructured":"15 Costa RF, Pires JA, Herrer\u00edas R, Fukumori NT, Gastiglia S, Barboza MF, et al. Labeling of DOTATATE with 68Ga: preliminary studies at IPEN - CNEN\/SP. Alasbimn J.; 2009. p. 12. In: XXII Congreso de Alasbimn, 2009, Cartagena de Indias, Colombia; 2009.","journal-title":"Alasbimn J."},{"key":"key20251126145529_B16","volume-title":"Theranostics, gallium-68, and other radionuclides: a pathway to personalized diagnosis and treatment; Richard P. Baum, Frank R\u00f6sch","author":"Costa","year":"2013","unstructured":"16 Costa RF, Barboza MF, Osso J Jr. 67Ga and 68Ga purification studies: preliminary results. In: Baum RP, R\u00f6sch F, editors. Theranostics, gallium-68, and other radionuclides: a pathway to personalized diagnosis and treatment; Richard P. Baum, Frank R\u00f6sch. Heidelberg, New York: Springer Verlag; 2013."},{"issue":"11","key":"key20251126145529_B17","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","unstructured":"17 Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256-61.","journal-title":"Cancer"},{"issue":"9","key":"key20251126145529_B18","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","article-title":"Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients","volume":"48","author":"Afshar-Oromieh","year":"2021","unstructured":"18 Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48(9):2925-34.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"key20251126145529_B19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","unstructured":"19 Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, V\u00f6\u00f6 S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43(3):397-403.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"key20251126145529_B20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer","volume":"195","author":"Maurer","year":"2016","unstructured":"20 Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-43.","journal-title":"J Urol"},{"issue":"5","key":"key20251126145529_B21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","unstructured":"21 Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668-74.","journal-title":"J Nucl Med"},{"issue":"6","key":"key20251126145529_B22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","unstructured":"22 Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014-24.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"key20251126145529_B23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/ph14050385","article-title":"Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer","volume":"14","author":"Fuscaldi","year":"2021","unstructured":"23 Fuscaldi LL, Sobral DV, Durante AC, Mendon\u00e7a FF, Miranda AC, da Cunha ML, et al. Standardization of the [68Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2021;14(5):385.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"key20251126145529_B24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-020-0594-6","article-title":"Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients","volume":"10","author":"Ringheim","year":"2020","unstructured":"24 Ringheim A, Campos Neto GC, Anazodo U, Cui L, da Cunha ML, Vitor T, et al. Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients. EJNMMI Res. 2020;10(1):12.","journal-title":"EJNMMI Res"},{"key":"key20251126145529_B25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nucmedbio.2018.04.003","article-title":"Gallium-68 labeled Ubiquicidin derived octapeptide as a potential infection imaging agent","volume":"62-63","author":"Bhatt","year":"2018","unstructured":"25 Bhatt J, Mukherjee A, Shinto A, Koramadai Karuppusamy K, Korde A, Kumar M, et al. Gallium-68 labeled Ubiquicidin derived octapeptide as a potential infection imaging agent. Nucl Med Biol. 2018;62-63:47-53.","journal-title":"Nucl Med Biol"},{"issue":"2","key":"key20251126145529_B26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2967\/jnumed.117.200048","article-title":"68Ga-NOTA-functionalized ubiquicidin: cytotoxicity, biodistribution, radiation dosimetry and first-in-human positron emission tomography\/computed tomography imaging of infections","volume":"59","author":"Ebenhan","year":"2018","unstructured":"26 Ebenhan T, Sathekge M, Lengana T, Koole M, Gheysens O, Govender T, et al. 68Ga-NOTA-functionalized ubiquicidin: cytotoxicity, biodistribution, radiation dosimetry and first-in-human positron emission tomography\/computed tomography imaging of infections. J Nucl Med. 2018;59(2):334-9.","journal-title":"J Nucl Med"},{"issue":"9","key":"key20251126145529_B27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpba.2018.06.064","article-title":"68Ga-NOTA-ubiquicidin fragment for PET imaging of infection: from bench to bedside","volume":"159","author":"Mukherjee","year":"2018","unstructured":"27 Mukherjee A, Bhatt J, Shinto A, Korde A, Kumar M, Kamaleshwaran K, et al. 68Ga-NOTA-ubiquicidin fragment for PET imaging of infection: from bench to bedside. J Pharm Biomed Anal. 2018;159(9):245-51.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"key20251126145529_B28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/ph17010048","article-title":"Radiosynthesis Standardization and Preclinical Assessment of the [68Ga]Ga-DOTA-Ubiquicidin29-41: A Translational Study Targeting Differential Diagnosis of Infectious Processes","volume":"17","author":"Miranda","year":"2023","unstructured":"28 Miranda AC, Fuscaldi LL, Mejia J, da Silva FF, Turato WM, Mendon\u00e7a FF, et al. Radiosynthesis Standardization and Preclinical Assessment of the [68Ga]Ga-DOTA-Ubiquicidin29-41: A Translational Study Targeting Differential Diagnosis of Infectious Processes. Pharmaceuticals (Basel). 2023;17(1):48.","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20251126145529_B29","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2023RC0621","article-title":"Antimicrobial peptide for bacterial infection imaging: first case reported in Brazil","volume":"21","author":"Nogueira","year":"2023","unstructured":"29 Nogueira SA, Barboza MR, Bezerra RP, Cabeza JM, Dell\u2019Aquila AM, Santos DD, et al. Antimicrobial peptide for bacterial infection imaging: first case reported in Brazil. einstein (Sao Paulo). 2023;21:eRC0621.","journal-title":"einstein (Sao Paulo)"},{"key":"key20251126145529_B30","first-page":"S953","article-title":"Successful applicability of 68Ga-UBI for debridement surgery in chronic osteomyelitis patient","volume":"51","author":"Nogueira","year":"2024","unstructured":"30 Nogueira S, da Luz FA, Iacone V, Caiado PL, Barboza MF, Osawa A, et al. Successful applicability of 68Ga-UBI for debridement surgery in chronic osteomyelitis patient. Eur J Nucl Med Mol Imaging. 2024;51 Suppl 1:S953.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"key20251126145529_B31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","unstructured":"31 Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39(3):783-803.","journal-title":"Cancer Metastasis Rev"},{"issue":"19","key":"key20251126145529_B32","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.3390\/cancers13194946","article-title":"FAP and FAPI-PET\/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis?","volume":"13","author":"Dendl","year":"2021","unstructured":"32 Dendl K, Koerber SA, Kratochwil C, Cardinale J, Finck R, Dabir M, et al. FAP and FAPI-PET\/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers (Basel). 2021;13(19):4946.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"key20251126145529_B33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts","volume":"59","author":"Loktev","year":"2018","unstructured":"33 Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59(9):1423-9.","journal-title":"J Nucl Med"},{"issue":"6","key":"key20251126145529_B34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","unstructured":"34 Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019;60(6):801-5.","journal-title":"J Nucl Med"},{"issue":"8","key":"key20251126145529_B35","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","unstructured":"35 Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47(8):1820-32.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"key20251126145529_B36","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.htct.2024.04.059","article-title":"Automated synthesis and in vitro studies of [68GA]GA-FAPI-46 in hospital radiopharmacy","volume":"46","author":"Fuscaldi","year":"2024","unstructured":"36 Fuscaldi LL, Lupinari PC, Sato KA, Miranda AC, Nogueira SA, Vitor T, et al. Automated synthesis and in vitro studies of [68GA]GA-FAPI-46 in hospital radiopharmacy. Hematol Transfus Cell Ther. 2024;46 Suppl 2:S6-7.","journal-title":"Hematol Transfus Cell Ther"},{"key":"key20251126145529_B37","first-page":"S306","article-title":"Comparison between PET\/CT with 68Ga-FAPI46 and FDG for the detection of primary and metastatic lesions in patients with diferent types of cancer. Initial experience","volume":"51","author":"Yamaga","year":"2024","unstructured":"37 Yamaga LY, Teles GB, Santos DB, Smaletz O, Pestana R, Blasi P, et al. Comparison between PET\/CT with 68Ga-FAPI46 and FDG for the detection of primary and metastatic lesions in patients with diferent types of cancer. Initial experience. Eur J Nucl Med Mol Imaging. 2024;51 Suppl 1:S306.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:55:42Z","timestamp":1764168942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/implementation-of-positron-emission-tomography-radiopharmaceuticals-labeled-with-gallium-68-in-a-hospital-radiopharmacy-experience-with-more-than-7500-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":37,"alternative-id":["10.31744\/einstein_journal\/2025AE1552"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025ae1552","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eAE1552"}}